Compare CARR & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CARR | RVMD |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.3B | 40.3B |
| IPO Year | 2020 | 2020 |
| Metric | CARR | RVMD |
|---|---|---|
| Price | $54.21 | $193.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 26 | 24 |
| Target Price | $73.66 | ★ $259.14 |
| AVG Volume (30 Days) | ★ 6.1M | 2.2M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $21,747,000,000.00 | N/A |
| Revenue This Year | $7.13 | N/A |
| Revenue Next Year | $5.65 | $564.95 |
| P/E Ratio | $196.54 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $50.24 | $49.05 |
| 52 Week High | $76.76 | $224.31 |
| Indicator | CARR | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 37.51 | 44.06 |
| Support Level | $53.84 | $188.18 |
| Resistance Level | $56.63 | $194.19 |
| Average True Range (ATR) | 1.19 | 8.63 |
| MACD | 0.16 | -1.27 |
| Stochastic Oscillator | 19.75 | 41.68 |
Carrier Global, spun out of United Technologies in 2020, manufactures and services commercial and residential HVAC systems and transportation refrigeration solutions under its flagship Carrier brand, as well as Bryant, Payne, Heil, and others across various price points. In 2024, Carrier acquired Viessmann Climate Solutions to expand its footprint in Europe with heat pumps, boilers, and solar PV equipment. Proceeds from the sale of Carrier's fire and security (Honeywell) and commercial refrigeration (Haier) businesses reduced debt and focused the company on global HVAC and refrigeration solutions. Carrier generates 75% of sales from equipment and 25% from parts and services. The company derives 50% of revenue from the US, 30% from Europe, and 20% from the Asia-Pacific region.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.